2023 North America Conference on Lung Cancer (NACLC) Highlights Webinar
Webinar | English | 60 Min
Image For Activity Cover
Credit Offered
1 ACCME Credit
1 Certificate of Attendance Credit
The IASLC Education committee present sa one-hour live session focused on the review and discussion of the most impactful and important topics presented at the 2023 IASLC North American Conference on Lung Cancer (NACLC) meeting. 
Live Activity Date: December 7, 2023
Enduring Activity Launch Date: Dec 22, 2023
Enduring Activity Expiration Date:Dec 21, 2024
Physicians, nurses, allied health professionals, pharmacists, and patient advocate​s. 
Upon completion of this activity, the participants should be able to: 
  • Identify the latest developments in immunotherapy for lung cancer in the neoadjuvant and adjuvant setting.
  • Summarize the latest discoveries of targeted therapy and new indications.
  • Evaluate the latest multidisciplinary lung cancer care among radiation therapy, thoracic surgery, and medical oncology.  
  • Luiz Raez, MD, FACP, FCCP, Chief Scientific Officer & Medical Director, Professor, Memorial Cancer Institute, Pembroke Pines, FL, USA
  • Mohamed Abazeed, MD, PhD, Radiation Oncologist, Scientist, Professor, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
  • Christine Bestivina, MD, Thoracic Oncologist, University of Chicago Medicine, Chicago, IL, USA
  • Jyoti Patel, MD, Medical Oncologist, Northwestern University, Evanston, IL, USA
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Christina Bestvina AstraZeneca, BMS Research Funding/Investigator Speaker
  AstraZeneca, BMS, CVS, Daiichi Sankyo, EMD Serono, Gilead, Mirati, Novocure, Regeneron, Sanofi, Takeda, Tempus Consulting, Advisory Board Speaker
Jyoti Patel AnHeart, AstraZeneca, BluePrint, BMS, Daiichi Sankyo, EMD Serono, Gilead, Sanofi, Takeda, Tempus Consulting, Advisory Board Speaker
Mohamed Abazeed Mirati Therapeutics, Bayer AG, Siemens Healthineers, Medscape Advisory Board, Research Funding, Educational Content (respectively) Speaker
Luis Raez AstraZeneca Research/Investigator Planner, Moderator
  AstraZeneca, Roche, MDS Speaker  

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

The International Association for the Study of Lung Cancer designates the live or enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:
  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
  4. Complete the activity evaluation to provide feedback for future programming and receive credit.
You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email: education@iaslc.org.
Powered By